added tables and references to intro

Latex/Paper/sections/01_introduction.tex

@@ -16,31 +16,51 @@ are common
 One essential step to introduce a novel pharmaceutical - or even
 to begin selling a generic compound - is to establish that the drug as packaged and sold will
 have acceptable safety and efficacy profiles.
-When evaluating these compounds in a clinical trial, both outcomes are possible:
+When evaluating these compounds in a clinical trial, multiple outcomes are possible:
 \begin{enumerate}
-    \item The compound demonstrates sufficient safety and efficacy, and proceeds in the appoval process. \ref{Item:EndSuccess}
+    \item The compound demonstrates sufficient safety and efficacy, and proceeds in the appoval process. 
-    \item The compound fails to demonstrate sufficient safety and efficacy, and the approval process halts. \ref{Item:EndFail}
+        \label{Item:EndSuccess}
-    \item The trial is terminated before it can acheive one of the first two outcomes, for reasons unrelated to safety and efficacy concerns. \label{Item:Terminate}
+    \item The compound fails to demonstrate sufficient safety and efficacy, and the approval process halts. 
+        \label{Item:EndFail}
+    \item The trial is terminated before it can acheive one of the first two 
+        outcomes, for reasons unrelated to safety and efficacy concerns. 
+        \label{Item:Terminate}
 \end{enumerate}
 
+
 \begin{table}
-    \caption{}\label{tab:}
+    \caption{Potential States of Knowledge from a clinical trial}\label{tab:StatesOfKnowledge}
     \begin{center}
-        \begin{tabular}{p{0.4\textwidth}|p{0.3\textwidth}|p{0.3\textwidth}|}
+        \begin{tabular}{p{0.15\textwidth} p{0.2\textwidth}||p{0.25\textwidth}|p{0.25\textwidth}|}
-        \cline{2-3}
+        \cline{3-4}
-          \multirow{2}{*}{}  & \multicolumn{2}{c|}{Drug-Indication Match} \\
+            \multicolumn{2}{c|}{Drug-Indication Match}  & safe and efficacious & not safe or not efficatious \\
-        \cline{2-3}
+        \hline
-            & safe and efficacious & not safe nor efficatious \\
         \hline
-        \multirow{2}{*}{Discovery process} & Known good & Known bad \\
+            \multirow{2}{0.15\textwidth}{Operations} & Success & Known good & Known bad \\
-        \cline{2-3}
+        \cline{2-4}
-            & Unknown & Unkown \\
+            & Failure & \multicolumn{2}{c|}{Unkown} \\
-        \cline{2-3}
+        \cline{2-4}
         \end{tabular}
     \end{center}
 \end{table}
 
 
+\begin{table}
+    \caption{Clinical Trial end states}\label{tab:ClinicalTrialEndStates}
+    \begin{center}
+        \begin{tabular}{p{0.15\textwidth} p{0.2\textwidth}||p{0.25\textwidth}|p{0.25\textwidth}|}
+        \cline{3-4}
+            \multicolumn{2}{c|}{Drug-Indication Match}  & safe and efficacious & not safe or not efficatious \\
+        \hline
+        \hline
+            \multirow{2}{0.15\textwidth}{Operations} & Success & Completion & Completion or Termination \\
+        \cline{2-4}
+            & Failure & \multicolumn{2}{c|}{Termination} \\
+        \cline{2-4}
+        \end{tabular}
+    \end{center}
+\end{table}
+
 While it is known that pharmaceutical companies withdraw some drugs from
 their development pipeline due to commercialization concerns 
 (